Dostarlimab vs Pembrolizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Dostarlimab

Marketed by GlaxoSmithKline and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04655976 · Phase 2/3 · active, not recruiting

Patients were randomly assigned to three arms (758 enrolled) with docetaxel as the active comparator, but the study was open label, with no masking. The primary endpoint, overall survival, was not significantly improved by dostarlimab plus docetaxel (HR 0.96, 95% CI 0.77 to 1.20, p=0.37) or by the triplet with cobolimab (HR 0.85, 95% CI 0.68 to 1.06, p=0.08), so the primary comparisons were not met.

Next expected readout: January 2027 · NCT06879717 (registry estimate)

Reported efficacy

Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks); Overall Survival (OS) (Arm B Versus Arm C) (Up to approximately 234 weeks): Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) (missed)

Result source: NCT04655976

Pembrolizumab

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT02142738 · Phase 3 · completed

The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).

Next expected readout: November 2026 · NCT06545331 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)

Result source: NCT02142738

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDostarlimabPembrolizumab
PFS, median4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results
OS, median11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results
ORR18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474
Duration of response, median8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results

PFS, median

Dostarlimab
4.4 vs 4.1vs Docetaxeln 305NCT04655976
2 other results
Pembrolizumab
8.8 vs 4.9+3.9 vs placebon 410NCT02578680
17 other results

OS, median

Dostarlimab
11.9 vs 11.3vs Docetaxeln 305NCT04655976
3 other results
Pembrolizumab
15.9 vs 11.3+4.6 vs placebon 278NCT02775435
15 other results

ORR

Dostarlimab
18.7% vs 14.5%vs Docetaxeln 305NCT04655976
2 other results
Pembrolizumab
47.6% vs 18.9%+28.7 vs placebon 410NCT02578680
14 other results
  • 57.9% vs 38.4% n 278 · Phase 3 · secondary NCT02775435
  • 29% vs 27.1% n 245 · Phase 3 · secondary NCT03515837
  • 39.1% vs 32% wk 191 · n 299 · Phase 3 · secondary NCT02220894
  • 33.2% vs 28.9% wk 191 · n 413 · Phase 3 · secondary NCT02220894
  • 27.2% vs 26.5% wk 191 · n 637 · Phase 3 · secondary NCT02220894
  • 44.8% vs 27.8% n 154 · Phase 3 · secondary NCT02142738
  • 22.7% vs 14.3% n 185 · Phase 3 · secondary NCT03976375
  • 22.7% vs 12.5% n 185 · Phase 3 · secondary NCT03976375
  • 28.1% vs 7.1% n 114 · Phase 3 · secondary NCT02864394
  • 20.7% vs 5.7% n 213 · Phase 3 · secondary NCT02864394
  • 5.4% vs 11.1% n 37 · Phase 2 · primary NCT04165096
  • 71.4% n 112 · Phase 2 · primary NCT03631784
  • 75.5% n 102 · Phase 2 · primary NCT03631784
  • 22% vs 28% n 69 · Phase 2 · secondary NCT03971474

Duration of response, median

Dostarlimab
8.3 vs 8.8vs Docetaxeln 57NCT04655976
2 other results
Pembrolizumab
11.2 vs 7.8+3.4 vs placebon 195NCT02578680
8 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Dostarlimab: 7 of 8 rows · Pembrolizumab: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDostarlimab
Rows use multiple source trials
Pembrolizumab
Rows use multiple source trials
Duration of Response
time to event · months
No placebo or comparator arm
21.5 monthsa,b
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
12.5 monthsc,a,b
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
NA months
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
ORR
responder rate · % of participants
No placebo or comparator arm
9.1% (n=11)d,b
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
71.4% (n=112)c,d,b
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
75.5% (n=102)
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
Overall Survival
time to event · months
No placebo or comparator arm
11.9 monthsc,e,d,b
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 1 more dose
11.8 months
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
20.7 monthsc,e,d,b
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
23 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
PFS
time to event · months
No placebo or comparator arm
4.4 monthsf,d,b
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
7.1 monthsc,f,d,b
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more dose
8.3 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
25.6%Cobolimab + Dostarlimab + Docetaxeg
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
21.6%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumabh
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
54%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
58.8%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
n/a: no completion milestone
NCT02775435 · Phase 3 · combination
n/a: no completion milestone
NCT02220894 · Phase 3
n/a: no completion milestone
NCT02504372 · Phase 3
89.3%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
33%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
0%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02864394 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT03850444 · Phase 3 · registry result, not featured evidence
2.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
90.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
0%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
50%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
80.7%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
89.2%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
94.4%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02955758 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
3.2%
NCT02733159 · Phase 2 · registry result, not featured evidence
87.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
86.4%
NCT03087760 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—Cobolimab + Dostarlimab + Docetaxeg
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
—Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
—Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
8.4%Pembrolizumabh
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
—Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
4.9%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
6.7%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
—Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
11.5%
NCT02775435 · Phase 3 · combination
19.9%
NCT02220894 · Phase 3
—
NCT02504372 · Phase 3
—200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
—Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
—Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
—Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
3.1%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
—
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
—
NCT02864394 · Phase 3 · registry result, not featured evidence
12.5%
NCT03850444 · Phase 3 · registry result, not featured evidence
—
NCT03634241 · Phase 2 · registry result, not featured evidence
—Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
—800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
—
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
—Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
—Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
—1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
—
NCT02955758 · Phase 2 · registry result, not featured evidence
—Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02733159 · Phase 2 · registry result, not featured evidence
12.3%
NCT03004183 · Phase 2 · registry result, not featured evidence
11.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
—
NCT03087760 · Phase 2 · registry result, not featured evidence
Serious AEs
33.8%Cobolimab + Dostarlimab + Docetaxeg
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 3 more results
42.7%Dostarlimab + Docetaxel (Arm B)
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
58.3%Stage 2 (Cohort 1A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Stage 2 (Cohort 2A): Niraparib + T
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
—Pembrolizumabh
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 48 more results
51.3%Pembrolizumab First Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
16.7%Pembrolizumab Second Course
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
38.8%10 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
—2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
36.6%2 mg/kg
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
57.5%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
22.2%Pembrolizumab+Pemetrexed+Platinum
NCT02578680 · Phase 3 · combination
46%
NCT02775435 · Phase 3 · combination
41%
NCT02220894 · Phase 3
24.5%
NCT02504372 · Phase 3
20.7%200 mg IV Q3W
NCT03715205 · Phase 4 · registry result, not featured evidence
35%Pembrolizumab (First Course) + Ola
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
37.7%Pembrolizumab (First Course) + Pem
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
0%Pembrolizumab (Second Course) + Ol
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
7.7%Pembrolizumab (Second Course) + Pe
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Olaparib (Maintena
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab + Pemetrexed (Mainte
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
23.4%Pembrolizumab + Pemetrexed + Plati
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
50%Arm 1 Stereotactic Body Radiation
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
100%Arm 2 Pembrolizumab Only
NCT03867175 · Phase 3 · registry result, not featured evidence
54.7%Pembrolizumab + Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
—Pembrolizumab+Lenvatinib
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
35.1%
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
53.8%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
36%
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
36.2%
NCT02864394 · Phase 3 · registry result, not featured evidence
32.8%
NCT03850444 · Phase 3 · registry result, not featured evidence
7.5%
NCT03634241 · Phase 2 · registry result, not featured evidence
9.5%Arm B (SCCHN)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
20%Arm C (mUBC)
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
60.8%800 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
46.7%200 mg
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
52.5%Pembrolizumab + Lenvatinib
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
47.6%Pembrolizumab + Quavonlimab
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
37.8%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
10.8%Untreated Brain Metastases From Me
NCT02681549 · Phase 2 · registry result, not featured evidence
20%Untreated Brain Metastases From NS
NCT02681549 · Phase 2 · registry result, not featured evidence
47.4%1st Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
54.1%2nd Line HNSCC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
25%2nd Line NSCLC
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
36%
NCT02955758 · Phase 2 · registry result, not featured evidence
58.9%Pembrolizumab + cCRT + Paclitaxel
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
45.1%Pembrolizumab + cCRT + Pemetrexed
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
85%
NCT02733159 · Phase 2 · registry result, not featured evidence
51.8%
NCT03004183 · Phase 2 · registry result, not featured evidence
40.6%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
45.5%
NCT03087760 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
g
anaemia 34.8%
neutropenia 31.5%
fatigue 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
show 2 more results
anaemia 31.5%
fatigue 29.8%
diarrhoea 29.5%
NCT04655976 · Phase 2/3 · combination · Non-Small Cell Lung Cancer · phase 2/3
nausea 58.3%
diarrhoea 50%
fatigue 41.7%
NCT03308942 · Phase 2 · registry result, not featured evidence · combination
h
diarrhoea 26.6%
dyspnoea 26.6%
fatigue 24%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 42 more results
upper respiratory tract infection 33.3%
constipation 16.7%
decreased appetite 16.7%
NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
10 mg/kg
fatigue 25.7%
decreased appetite 23.3%
dyspnoea 23%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
2 mg/kg
decreased appetite 30.7%
fatigue 30.1%
nausea 25.7%
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
nausea 57.3% (placebo 51%)
anaemia 45.9% (placebo 45%)
fatigue 42.7% (placebo 39.6%)
NCT02578680 · Phase 3 · combination
abdominal pain 22.2% (placebo 6.4%)
cough 22.2% (placebo 30.7%)
diarrhoea 22.2% (placebo 20.3%)
NCT02578680 · Phase 3 · combination
anaemia 53.2% (placebo 49.6%)
alopecia 46% (placebo 37.5%)
nausea 36.3% (placebo 32.1%)
NCT02775435 · Phase 3 · combination
decreased appetite 17%
cough 16.8%
dyspnoea 16.5%
NCT02220894 · Phase 3
weight increased 22.8% (placebo 28.9%)
pruritus 21.6% (placebo 12.7%)
hypothyroidism 20.7% (placebo 4.6%)
NCT02504372 · Phase 3
200 mg IV Q3W
hypothyroidism 17.3%
anaemia 12.7%
constipation 11.3%
NCT03715205 · Phase 4 · registry result, not featured evidence
anaemia 36.2%
nausea 24%
fatigue 17.2%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 37.7%
nausea 19%
aspartate aminotransferase increased 16.6%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 14.3%
covid-19 14.3%
headache 14.3%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 15.4%
cough 15.4%
productive cough 15.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anaemia 38.4%
nausea 30.9%
neutropenia 23.4%
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
anemia 75%
cough 75%
abdominal pain 50%
NCT03867175 · Phase 3 · registry result, not featured evidence · combination
alanine aminotransferase increased 100%
alkaline phosphatase increased 100%
aspartate aminotransferase increased 100%
NCT03867175 · Phase 3 · registry result, not featured evidence
hypertension 41.4%
diarrhoea 40.9%
hypothyroidism 35.4%
NCT03976375 · Phase 3 · registry result, not featured evidence · combination
anaemia 40.4% (placebo 44.7%)
nausea 39.2% (placebo 43.5%)
neutrophil count decreased 36.7% (placebo 45.9%)
NCT03515837 · Phase 3 · registry result, not featured evidence · combination
alopecia 78.5%
white blood cell count decreased 78.5%
neutrophil count decreased 76.9%
NCT03875092 · Phase 3 · registry result, not featured evidence · combination
nausea 72% (placebo 53.3%)
constipation 64% (placebo 73.3%)
decreased appetite 56% (placebo 60%)
NCT03950674 · Phase 3 · registry result, not featured evidence · combination
anaemia 33.3%
aspartate aminotransferase increased 21.6%
cough 21.6%
NCT02864394 · Phase 3 · registry result, not featured evidence
anaemia 30.5%
cough 23.4%
pyrexia 22.7%
NCT03850444 · Phase 3 · registry result, not featured evidence
fatigue 45%
investigations 25%
alanine aminotransferase increased 20%
NCT03634241 · Phase 2 · registry result, not featured evidence
anaemia 42.9%
diarrhoea 33.3%
fatigue 28.6%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
asthenia 40%
blood creatinine increased 40%
blood urea increased 40%
NCT05077709 · Phase 2 · registry result, not featured evidence · combination
800 mg
diarrhoea 29.4%
fatigue 21.6%
alanine aminotransferase increased 19.6%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
200 mg
pyrexia 23.3%
constipation 20%
decreased appetite 20%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
hypertension 52.5%
diarrhoea 45%
hypothyroidism 36.3%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
pruritus 29.3%
cough 22%
fatigue 20.7%
NCT03516981 · Phase 2 · registry result, not featured evidence · combination
fatigue 29.7%
pruritus 29.7%
nausea 24.3%
NCT04165096 · Phase 2 · registry result, not featured evidence · combination
headache 40.5%
fatigue 24.3%
rash 21.6%
NCT02681549 · Phase 2 · registry result, not featured evidence
anorexia 40%
gastrointestinal disorders - other, specify 40%
hypertension 40%
NCT02681549 · Phase 2 · registry result, not featured evidence
asthenia 34.2%
dyspnoea 34.2%
cough 29.8%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
asthenia 21.6%
anaemia 18.9%
cough 18.9%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
decreased appetite 36.1%
dyspnoea 36.1%
cough 30.6%
NCT03625323 · Phase 2 · registry result, not featured evidence · combination
nausea 24%
decreased appetite 20%
worsening abdominal pain 20%
NCT02955758 · Phase 2 · registry result, not featured evidence
anaemia 39.3%
fatigue 34.8%
alopecia 31.3%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
nausea 52%
asthenia 40.2%
anaemia 32.4%
NCT03631784 · Phase 2 · registry result, not featured evidence · combination
fatigue 60%
dyspnea 48.3%
cough 35%
NCT02733159 · Phase 2 · registry result, not featured evidence
fatigue 21.4%
nausea 12.5%
back pain 10.7%
NCT03004183 · Phase 2 · registry result, not featured evidence
fatigue 56.5%
hypoalbuminemia 44.9%
hyponatremia 39.1%
NCT03971474 · Phase 2 · registry result, not featured evidence · combination
esophagitis 36.4%
fatigue 36.4%
hypothyroidism 22.7%
NCT03087760 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation context differs: registered conditions differ.
  2. bThe assessment timepoint is not available for both results.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation comparability has not been reviewed for both studies.
  5. eTrial phases differ: Phase 3 versus Phase 2/3.
  6. fTrial phases differ: Phase 3 versus Phase 2.
  7. gPopulation comparability has not been reviewed for 2 of these studies.
  8. hPopulation comparability has not been reviewed for 42 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dostarlimab

Disease Control 54.5% (n=11)
responder rate · % of participants
No placebo or comparator arm
NCT03308942 · Phase 2 · registry result, not featured evidence · combination

Pembrolizumab

PFS Rate at 6 62.1% (n=154) vs 50.3% (n=151) SOC Chemotherapy @ 24wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
OS Rate at 12 70.3% (n=154) vs 54.8% (n=151) SOC Chemotherapy @ 48wk
responder rate · % of participants
NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 12.7 vs 8.5 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
10.4 vs 8.5 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
PFS 4 vs 4 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
3.9 vs 4 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
ORR 18.5% (n=346) vs 9.3% (n=343) Docetaxel10 mg/kg
responder rate · % of participants
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
18% (n=344) vs 9.3% (n=343) Docetaxel2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Duration of Response NA vs 6.23 Docetaxel months10 mg/kg
time to event · months
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
show 1 more result
NA vs 6.23 Docetaxel months2 mg/kg
All PD-L1 Positive
NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3
Disease-free Survival 53.8 vs 43 placebo months
time to event · months
NCT02504372 · Phase 3
show 3 more results
67 vs 47.6 placebo months
NCT02504372 · Phase 3
58.7 vs 42.8 placebo months
NCT02504372 · Phase 3
53.6 vs 42 placebo months @ 295wk
NCT02504372 · Phase 3
EORTC QLQ-C30 GHS -5.34 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-3.44 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
Time to Deterioration Global Health Status 19.81 months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
17.28 months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-LC13 -1.98 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
-1.82 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
-0.82 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
-0.47 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
Time to Deterioration QLQ-LC13 NA months
time to event · months
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
NA months
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Dyspnoea -0.16 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT03976323 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
1.35 score @ 24wk
NCT03976323 · Phase 3 · registry result, not featured evidence · combination

+ 40 further endpoints in the CSV export.

Endometrial Cancer

Shared mechanism: PD-1 · full Endometrial Cancer pipeline

Dostarlimab

Marketed by GlaxoSmithKline and partners

Approved in Endometrial Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT03981796 (registry estimate)

No aligned efficacy figure on record for this race.

Pembrolizumab

Marketed by Merck & Co.

Approved in Endometrial Cancermonoclonal antibody
Reliable signal

NCT03914612 · Phase 3 · active, not recruiting

This was a randomized, double-blind, placebo-controlled phase 3 trial with a power calculation reported in its protocol, run as two cohorts of 225 dMMR and 588 pMMR patients. Its primary endpoint, progression-free survival, was significantly longer with pembrolizumab plus chemotherapy than with placebo plus chemotherapy in both cohorts (hazard ratios 0.30 and 0.54, both P<0.001).

Next expected readout: December 2026 · NCT04585750 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Duration of time from study entry to time of progression per RECIST criteria or death due to any cause, whichever occurs first. The interquartile range for follow-up was (6.37 months, 30.62 months). The maximum for follow-up was 37.85 months.): PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023). (met)

Result source: NCT03914612

Results for Endometrial Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Dostarlimab: no structured comparison results are available for Endometrial Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Pembrolizumab
PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023). NCT03914612 · Phase 3 · design grade: strong · publication or press release
Available safety results

Pembrolizumab

Dropout rate
n/a: no completion milestone300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 4 more results
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
—300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 4 more results
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
45%300 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 4 more results
50%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
51%100 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
40%50 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
0%25 mg BID + 200 mg Q3W
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
300 mg BID + 200 mg Q3W
fatigue 65%
nausea 55%
vomiting 50%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
show 4 more results
100 mg BID + 200 mg Q3W
fatigue 50%
back pain 38.9%
diarrhoea 38.9%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
100 mg BID + 200 mg Q3W
fatigue 48.4%
nausea 30.1%
cough 26.2%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
50 mg BID + 200 mg Q3W
fatigue 65%
arthralgia 45%
nausea 45%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination
25 mg BID + 200 mg Q3W
arthralgia 100%
constipation 75%
cough 75%
NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dostarlimab's landscape · Pembrolizumab's landscape